On May 19, the COVID-19 Antigen Rapid Test (colloidal gold method) independently developed by Guangzhou Weimi Bio-Tech Co., Ltd (“Weimi Bio-Tech”) successfully obtained the EU CE certificate. This certification signifies that Weimi Bio-Tech 's COVID-19 Antigen Rapid Test products can be sold in EU countries and countries that recognize EU CE certification.

Weimi Bio-Tech's COVID-19 Antigen Rapid Test is used for the in vitro qualitative detection of 2019-nCoV N antigen in human nasal swab samples and can also be used for patient self-testing. The COVID-19 Antigen Test is only used as an adjunctive screening tool for coronavirus. If symptoms of suspected coronavirus infection are present, they need to be reported promptly and isolated and seen in accordance with prevention and control regulations.

The product is based on a colloidal gold method, which allows individuals to collect anterior nasal swabs without the need for testing equipment and obtain rapid test results. The product has the advantages of easy operation, short testing time and multiple applications, and can meet the needs of home testing for epidemic prevention and control in the EU.

About Weimi Bio-Tech

Guangzhou Weimi Bio-Tech Co., Ltd (“Weimi Bio-Tech”) was established in Sep. 2013, Located in South China Advanced Material Innovation Park, Science City, Guangzhou. As a high-technology company, Weimi Bio-Tech is dedicated to IVD field and focused on related Research & Development, manufactory and distribution.

Weimi Bio-Tech has been possessing Core technologies such as time-resolved immunofluorescence chromatography, colloidal gold chromatography, neuroimmunology, flow cytometry, enzyme-linked immunosorbent assay, biochemistry, etc. Its products cover the diagnosis of cardiovascular and cerebrovascular diseases, inflammation series, obstetrics and Gynecology series, cancer series, diabetes, nephropathy series and other diseases.